专利检索 ap:("Jean-Damien Charrier" OR "Pan Li" OR "Ronald Knegtel" OR "Julian Marian Charles Golec" OR "David Bebbington" OR "Hayley Marie Binch") AND inv:"Hayley Marie Binch" 第 1 页

1.

发明授权
Triazole compounds useful as protein kinase inhibitors 失效
标题翻译：可用作蛋白激酶抑制剂的三唑化合物

公开(公告)号：US08633210B2

公开(公告)日：2014-01-21

申请号：US13094183

申请日：2011-04-26

申请人： Jean-Damien Charrier , Pan Li , Ronald Knegtel , Julian Marian Charles Golec , David Bebbington , Hayley Marie Binch

发明人： Jean-Damien Charrier , Pan Li , Ronald Knegtel , Julian Marian Charles Golec , David Bebbington , Hayley Marie Binch

IPC分类号： A01N43/54 , A61K31/517 , C07D401/00 , C07D403/00 , C07D413/00 , C07D417/00 , C07D419/00

CPC分类号： C07D401/14 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/16 , C07D487/04 , C07D491/04 , C07D493/04 , C07D495/04 , C07D513/04

摘要： This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R1; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused ring; R1, R3, and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.

摘要翻译： 本发明描述了式IX的新型三唑化合物：其中Z1是氮或CR9，Z2是氮或CH，条件是Z1和Z2中的至少一个是氮; G是环C或环D; 环C选自苯基，吡啶基，嘧啶基，哒嗪基，吡嗪基或1,2,4-三嗪基，其中所述环C具有一个或两个独立地选自-R 1的邻位取代基; 环D是选自芳基，杂芳基，杂环基或碳环基的5-7元单环或8-10元双环; Rx和Ry独立地选自T-R3，或Rx和Ry与它们的插入原子一起形成稠环; R1，R3和T如说明书中所述。这些化合物可用作蛋白激酶抑制剂，特别是作为GSK-3和Aurora的抑制剂，用于治疗诸如糖尿病，癌症和阿尔茨海默病的疾病。

2.

发明授权
Compounds useful as inhibitors of ATR kinase 有权

公开(公告)号：US09630956B2

公开(公告)日：2017-04-25

申请号：US13106476

申请日：2011-05-12

申请人： Jean-Damien Charrier , Hayley Marie Binch , Dennis James Hurley , Thomas Cleveland , Pramod Joshi , Lev Tyler Dewey Fanning , Joanne Pinder , Michael O'Donnell , Anisa Nizarali Virani , Ronald Marcellus Alphonsus Knegtel , Steven John Durrant , Stephen Clinton Young , Pierre-Henri Storck , David Kay , Philip Michael Reaper , Matthew Paul Grote

发明人： Jean-Damien Charrier , Hayley Marie Binch , Dennis James Hurley , Thomas Cleveland , Pramod Joshi , Lev Tyler Dewey Fanning , Joanne Pinder , Michael O'Donnell , Anisa Nizarali Virani , Ronald Marcellus Alphonsus Knegtel , Steven John Durrant , Stephen Clinton Young , Pierre-Henri Storck , David Kay , Philip Michael Reaper , Matthew Paul Grote

IPC分类号： A61K31/497 , A61K33/24 , C07D413/14 , C07D401/14 , C07D241/10

CPC分类号： C07D413/14

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

3.

发明授权
Caspase inhibitors and uses thereof 失效
标题翻译：胱天蛋白酶抑制剂及其用途

公开(公告)号：US08288537B2

公开(公告)日：2012-10-16

申请号：US13309117

申请日：2011-12-01

申请人： Julian M. C. Golec , Paul S. Charifson , Jean-Damien Charrier , Hayley Marie Binch

发明人： Julian M. C. Golec , Paul S. Charifson , Jean-Damien Charrier , Hayley Marie Binch

IPC分类号： C07D215/38

CPC分类号： C07D209/48 , C07D209/46 , C07D213/64 , C07D215/227 , C07D217/24 , C07D239/36 , C07D239/80 , C07D239/88 , C07D239/90 , C07D471/04 , C07D495/04

摘要： This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are useful as caspase inhibitors. These compounds have the general formula I: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated or unsaturated five to seven membered ring containing zero to three heteroatoms, and provided that when X3 is a carbon, a substituent on X3 is attached by an atom other than nitrogen.

摘要翻译： 本发明提供可用作半胱天冬酶抑制剂的新化合物及其药学上可接受的衍生物。这些化合物具有通式I：其中R 1，R 2和R 3如本文所述，环A包含0至2个双键，每个X独立地选自氮或碳，环A中的至少一个X为氮，环A如所述任选被取代，并且可以与含有0至3个杂原子的饱和或不饱和的5至7元环稠合，并且条件是当X 3是碳时，X 3上的取代基被除氮以外的原子连接。

4.

发明申请
COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE 有权

公开(公告)号：US20120027874A1

公开(公告)日：2012-02-02

申请号：US13106476

申请日：2011-05-12

申请人： Jean-Damien Charrier , Hayley Marie Binch , Dennis James Hurley , Thomas Cleveland , Pramod Joshi , Lev Tyler Dewey Fanning , Joanne Pinder , Michael O'Donnell , Anisa Nizarali Virani , Ronald Marcellus Alphonsus Knegtel , Steven John Durrant , Stephen Clinton Young , Pierre-Henri Storck , David Kay , Philip Michael Reaper

发明人： Jean-Damien Charrier , Hayley Marie Binch , Dennis James Hurley , Thomas Cleveland , Pramod Joshi , Lev Tyler Dewey Fanning , Joanne Pinder , Michael O'Donnell , Anisa Nizarali Virani , Ronald Marcellus Alphonsus Knegtel , Steven John Durrant , Stephen Clinton Young , Pierre-Henri Storck , David Kay , Philip Michael Reaper

IPC分类号： A61K31/497 , A61K33/24 , A61P35/00 , C07D413/14

CPC分类号： C07D413/14

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

5.

发明授权
Caspase inhibitors and uses thereof 失效
标题翻译：胱天蛋白酶抑制剂及其用途

公开(公告)号：US07906650B2

公开(公告)日：2011-03-15

申请号：US12359749

申请日：2009-01-26

申请人： Julian M. C. Golec , Paul S. Charifson , Jean-Damien Charrier , Hayley Marie Binch

发明人： Julian M. C. Golec , Paul S. Charifson , Jean-Damien Charrier , Hayley Marie Binch

IPC分类号： C07D215/38

CPC分类号： C07D209/48 , C07D209/46 , C07D213/64 , C07D215/227 , C07D217/24 , C07D239/36 , C07D239/80 , C07D239/88 , C07D239/90 , C07D471/04 , C07D495/04

摘要： This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are useful as caspase inhibitors. These compounds have the general formula I: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated or unsaturated five to seven membered ring containing zero to three heteroatoms, and provided that when X3 is a carbon, a substituent on X3 is attached by an atom other than nitrogen.

摘要翻译： 本发明提供可用作半胱天冬酶抑制剂的新化合物及其药学上可接受的衍生物。这些化合物具有通式I：其中R 1，R 2和R 3如本文所述，环A包含0至2个双键，每个X独立地选自氮或碳，环A中的至少一个X为氮，环A如所述任选被取代，并且可以与含有0至3个杂原子的饱和或不饱和的5至7元环稠合，并且条件是当X 3是碳时，X 3上的取代基被除氮以外的原子连接。

6.

发明授权
Compounds useful as inhibitors of ATR kinase 有权
标题翻译：可用作ATR激酶抑制剂的化合物

公开(公告)号：US08410112B2

公开(公告)日：2013-04-02

申请号：US13104291

申请日：2011-10-27

申请人： Jean-Damien Charrier , Steven John Durrant , David Kay , Michael O'Donnell , Ronald Marcellus Alphonsus Knegtel , Somhairle MacCormick , Joanne Pinder , Stephen Clinton Young , Hayley Marie Binch , Thomas Cleveland , Lev Tyler Dewey Fanning , Dennis James Hurley , Pramod Joshi , Urvi Jagdishbhai Sheth , Alina Silina , Philip Michael Reaper , Anisa Nizarali Virani

发明人： Jean-Damien Charrier , Steven John Durrant , David Kay , Michael O'Donnell , Ronald Marcellus Alphonsus Knegtel , Somhairle MacCormick , Joanne Pinder , Stephen Clinton Young , Hayley Marie Binch , Thomas Cleveland , Lev Tyler Dewey Fanning , Dennis James Hurley , Pramod Joshi , Urvi Jagdishbhai Sheth , Alina Silina , Philip Michael Reaper , Anisa Nizarali Virani

IPC分类号： A61K31/4965 , C07D403/00

CPC分类号： C07D403/14 , A61K31/497 , A61K31/541 , A61K31/551 , A61K45/06 , C07D241/28 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D491/113

摘要： The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

摘要翻译： 本公开涉及式I的吡嗪化合物：其中L，n，R 1和R 2如说明书中所述。这些化合物可用作ATR蛋白激酶的抑制剂。本公开还涉及包含本公开内容的化合物的药学上可接受的组合物; 使用本公开的化合物治疗各种疾病，病症和病症的方法; 制备本公开的化合物的方法; 用于制备本公开的化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。

7.

发明授权
Caspase inhibitors and uses thereof 失效

公开(公告)号：US08093392B2

公开(公告)日：2012-01-10

申请号：US13022820

申请日：2011-02-08

申请人： Julian M. C. Golec , Paul S. Charifson , Jean-Damien Charrier , Hayley Marie Binch

发明人： Julian M. C. Golec , Paul S. Charifson , Jean-Damien Charrier , Hayley Marie Binch

IPC分类号： C07D215/38

CPC分类号： C07D209/48 , C07D209/46 , C07D213/64 , C07D215/227 , C07D217/24 , C07D239/36 , C07D239/80 , C07D239/88 , C07D239/90 , C07D471/04 , C07D495/04

摘要： This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are useful as caspase inhibitors. These compounds have the general formula I: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated or unsaturated five to seven membered ring containing zero to three heteroatoms, and provided that when X3 is a carbon, a substituent on X3 is attached by an atom other than nitrogen.